No Evidence of Increased Risk for Certain Highly Atherogenic Lipoprotein Phenotypes in HIV-infected Patients

Archives of Medical Research

Volumn 39, Issue 1, 2008, Pages 84-91

  Catzin Kuhlmann, Andrés ^a   Castillo Martínez, Lilia ^a   Colín Ramírez, Eloisa ^a   Valles, Victoria ^a   Aguilar Salinas, Carlos A ^a   Sierra, Juan ^a   Calva, Juan J ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Antiretroviral therapy; Apolipoproteins; Atherosclerosis; Dyslipidemia; Human immunodeficiency virus; Lipoproteins

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A; APOLIPOPROTEIN B; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EXPOSURE; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPOLIPOPROTEINEMIA; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; RANDOMIZATION;

ADULT; ANTI-HIV AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ATHEROSCLEROSIS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIAS; MALE; MEXICO; MIDDLE AGED; PHENOTYPE; PREVALENCE; RISK;

EID: 36549058260     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2007.06.012     Document Type: Article

References (23)

1. Friis-Møller N., Weber R., Reiss P., Thiebaut R., Kirk O., D'Arminio Monteforte A., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 17 (2003) 1179-1793
2. Fontas E., van Leth F., Sabin C.A., Friis-Moller N., Rickenbach M., D'Arminio Monforte A., et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?. J Infect Dis 189 (2004) 1056-1074
3. Riddler S.A., Smith E., Cole S.R., Li R., Chmiel J.S., Dobs A., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (2003) 2978-2982
4. Savès M., Chêne G., Ducimetière P., Leport C., Le Moal G., Amouyel P., et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37 (2003) 292-298
5. Assmann G., and Schulte H. Results and conclusions of the prospective cardiovascular Münster (PROCAM) study. In: Assmann G. (Ed). Lipid Metabolism Disorders and Coronary Heart Disease: Primary Prevention, Diagnosis and Therapy Guidelines for General Practice (1993), MMV Medizin Verlag, Munich 19-67
6. Austin M.A., King M.C., Vranizan K.M., and Krauss R.M. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82 (1990) 495-506
7. Talmud P.J., Hawe E., Miller G.J., and Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 22 (2002) 1918-1923
8. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., and Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358 (2001) 2026-2033
9. Domingo P., Sambeat M.A., Pérez A., and Ordoñez J. Effect of protease inhibitors on apolipoprotein B levels and plasma lipid profile in HIV-1-infected patients on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33 (2003) 114-116
10. Malavazi I., Abrão E.P., Mikawa A.Y., Landgraf V.O., and da Costa P.I. Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status. Clin Chem Lab Med 42 (2004) 525-532
11. Schmitz M., Michl G.M., Walli R., Bogner J., Bedyneck A., Seidel D., et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 26 (2001) 225-235
12. Catzin-Kuhlmann A., Orea-Tejeda A., Castillo-Martínez L., Colin-Ramirez E., Asz D., Aguirre V.H., et al. Human immunodeficiency virus infected subjects have no altered myocardial perfusion. Int J Cardiol (2007) Epub Jan 25, 2007
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
14. Sniderman A., Junger I., Holme I., Aastveit A., and Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 259 (2006) 455-461
15. Valles V., Aguilar-Salinas C.A., Gómez-Pérez F.J., Rojas R., Franco A., Olaiz G., et al. Apolipoprotein B and A-I distribution in Mexican adults: results of a nationwide survey. Metabolism 51 (2002) 560-568
16. Sniderman A.D., Furberg C.D., Keech A., Roeters van Lennep J.E., Frohlich J., Jungner I., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361 (2003) 777-780
17. Yusuf S., Hawken S., Ôunpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (2004) 937-952
18. Shahmanesh M., Das S., Stolinski M., Shojaee-Moradie F., Jackson N.C., Jefferson W., et al. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab 90 (2005) 755-760
19. Currier J.S., Kendall M.A., Zackin R., Henry W.K., Alston-Smith B., Torriani F.J., et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19 (2005) 927-933
20. Depairon M., Chessex S., Sudre P., Rodondi N., Doser N., Doser N., et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 15 (2001) 329-334
21. Talwani R., Falusi O.M., Mendes de Leon C.F., Nerad J.L., Rich S., Proia L.A., et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr 30 (2002) 191-195
22. Fauvel J., Bonnet E., Ruidavets J.B., Ferrieres J., Toffoletti A., Massip P., et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15 (2001) 2397-2406
23. Purnell J.Q., Zambon A., Knopp R.H., Pizzuti D.J., Achari R., Leonard J.M., et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14 (2000) 51-57